The global dermatology markets reached $15.8 billion in 2012. The market is expected to reach $16.1 billion in 2013 and $18.5 billion in 2018 for a CAGR of 2.8%.
This report provides:
- An overview of the global market for treatments of skin diseases, perhaps the most common of human afflications
- Analyses of global market trends, with data from 2011 and 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
- Focused coverage of four major categories of skin disease of exceptional medical and commercial significance: dermatitis (allergic and contact), cancers (including melanoma), immune disorders (including psoriasis), and infections (bacterial, fungal and viral)
- Topics such as skin structure and function, diseases of the skin, current treatment options, and unmet clinical needs
- Discussion of the evolution of the market, including the rising prevalence of some skin diseases, and new diagnostic and treatment options
- Examination of the global market by product categories, such as anti-allergic products, antibacterials, antifungals, antivirals, immunotherapies, and anticancers
- Comprehensive company profiles of major players.
MAJOR GLOBAL DERMATOLOGY MARKETS, 2011-2018
Source: BCC Research
Download Report Overview
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of the major skin diseases. Special emphasis is given to ongoing research into improved treatment modalities, especially those utilizing biological approaches. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on epidemiological data and projections plus information on R&D trends and their likely effects on market potential on a country-by-country basis.
REASONS FOR DOING THE STUDY
The dermatology market is facing a period of change after several years during which it was a relatively modest and slow-growing sector within the overall pharmaceutical environment. The advent of innovative therapies for some skin diseases has been a stimulus for renewed interest in this market among major pharma companies. New contenders in this market have emerged as small to medium-size companies evolve into medium to large concerns by a process of serial acquisitions. In this environment there is a need for an up-to-date and comprehensive appraisal of the dermatology marketplace, with a review of the most important diseases, portfolios and pipelines.
SCOPE OF REPORT
This report discusses the implications of the above-mentioned trends in the context of the current size and growth of the dermatology market, discussed both in global terms and in reference to the most important national markets. Long-standing and emerging companies are discussed, with profiles of their leaders and an update on M&A activity. Five-year global sales forecasts are provided for main drug categories, and breakdowns are provided for several national markets.
MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are projected at 2012 dollar value without an attempt to predict the effect of inflation/deflation. Therapeutic categories discussed include dermatitis, psoriasis, acne, lupus, skin infections (bacterial, fungal, viral) and skin cancers.
Primary research includes interviews with leading individuals in relevant companies and medical associations; primary sources of published data include epidemiological and economic studies, company annual reports, SEC filings and government publications. Secondary sources consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources and are critically assessed by BCC. In this report, “global” is defined as the sum of the following national markets: U.S., Japan, the leading five EU markets (Germany, France, Italy, Spain and U.K., abbreviated to EU5) and the four BRIC countries: Brazil, Russia, India and China. The rest of the world is thought to represent not much more than 10% of the actual global total, and there are few or no data for most of the countries that contribute to this segment, so we have left them out of the discussion.
This report is designed to satisfy the information needs of a wide variety of individuals involved in the dermatology marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.
Sources of information included marketing strategists, industry executives, government and professional agencies and surveys of physicians. Company annual reports and SEC filings, journal articles and data from healthcare institutions were also mined.
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of several previous BCC reports on diseases affecting different organ systems in addition to the skin.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders.
- Subscribe to any of BCC’s many industry newsletters.
- Read announcements of recently published reports and newly launched newsletters.
- Register for BCC’s well-known conferences.
- Request additional information on any BCC product.
- Take advantage of special offers.
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Download Report Overview